ArticleScientific reports2025
Pro-inflammatory effects of endogenous and recombinant MDA-7/IL-24 with RGD peptide on human hepatic stellate cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic stellate cells (HSCs) serve as pivotal mediators of liver fibrogenesis. This study investigates the pro-inflammatory effects of melanoma differentiation-associated gene-7/interleukin-24 (MDA-7/IL-24) within both murine and cellular models. By employing the hydrodynamic injection of a plasmid expressing IL-24/mda7 (PMDA-7) in mice, significant inflammatory histopathological alterations were observed in the liver tissue. In human LX-2 HSCs, treatment with recombinant IL-24 (rIL-24), as well as transfection with PMDA-7 or RGD-modified PMDA-7-RGD plasmids, resulted in an increased expression of pro-inflammatory cytokines (IL-1β, IL-6, IL-17, IL-18, IL-23) and regulatory molecules (SOCS1, SOCS3). Importantly, the RGD-modified variant exhibited the most pronounced effects, with PMDA-7-RGD inducing the highest levels of IL-1β, IL-6, IL-17, and IL-18 expression, whereas rIL-24 was noted to most effectively upregulate IL-23 (P < 0.05). These findings substantiate that MDA-7/IL-24 exerts pro-inflammatory effects on HSCs, which are further amplified by RGD conjugation, thus suggesting its potential involvement in the pathogenesis of liver inflammation and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.